Patients
Step Pharma is focused on bringing dencatistat to the patients who need it most. Step Pharma is running clinical trials in blood cancers and solid tumours.
Clinical trials in lymphoma were started in September 2022.
Clinical trials in solid tumours, which started July 2024, will test the safety and efficacy of dencatistat in biomarker selected patients whose tumours have lost expression of CTPS2.
STP938 has entered clinical trials for the treatment of blood cancers where STP938 could form the backbone of various treatment regimens with the potential for accelerated approval from a single arm phase 2 study.
Dencatistat (STP938) will enter clinical trials for the treatment of solid tumours with an initial focus on ovarian cancer but the potential to become a therapy for multiple solid tumour types based on biomarker selection for loss of CTPS2.
Find information about our clinical trials at clinicaltrials.gov
Step Pharma
15 rue Louis et Auguste Lumière
Technoparc du Pays-de-Gex
01630 Saint-Genis-Pouilly
France
